Home Stakeholders Health & Social Care Stakeholders Imcyse presents Imotopes™ – autoimmune disease treatment

Imcyse presents Imotopes™ – autoimmune disease treatment

ImotopesTM: a radically new approach to the treatment of autoimmune diseases – now entering Ph.2 testing in type 1 diabetes

Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe chronic autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven in 2011, Imcyse subsequently relocated to Liège, Belgium.

The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides – ImotopesTM, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.

With an initial focus on type 1 diabetes (T1D) our lead candidate, IMCY-0098, is a novel insulin-based ImotopeTM. T1D is an autoimmune disease in which beta-cells are destroyed due to an inadequate immune response. Thereby, the pancreas stops producing insulin, the hormone that controls blood-sugar levels. With IMCY-0098, we aim to intervene early in the autoimmune response to stop the destruction of beta-cells, by this means, the ability of the pancreas to naturally produce insulin is restored.

In a phase 1 study, IMCY-0098 was found to be safe and well tolerated; early signs of efficacy could also be detected. Preparations are now underway for a phase 2 study program – IMPACT – with leading T1D KOL Prof. Dr. Chantal Mathieu as principal investigator. The study is expected to begin in September 2020.

As a proud member of INNODIA, a global network of academic institutions, industrial partners, patient organizations and a small sized enterprise bringing their knowledge and experience together to fight T1D, Imcyse aims to leverage this private public partnership to gain greater access to T1D patient populations, a platform for scientific knowledge exchange and technical approaches to refine treatment with ImotopesTM as a safe and effective therapy for patients with early T1D.